CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating webbased and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs,

b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form-please include any quotes from your manuscript in QUOTATION MARKS,

or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF <code>_AND_</code> CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u>

doi: 10.2196/jmir.1923 PMID: 22209829

| 4.0 | _ | | |
|-----|----|----|-------|
| × , | 20 | am | ırad |
| | 10 | qu | ii Cu |

| Your name * | |
|-------------|--|
| First Last | |
| Hyeongju | |

| Seoul National University, Seoul, Repub | li - |
|---|--|
| Your e-mail address * abc@gmail.com | |
| rnyoo@snu.ac.kr | |
| Title of your manuscript * Provide the (draft) title of your manuscript. | |
| Efficacy of a "Healthy Lifestyle Coachir Application for Office Workers: An Expl | g Chatbot" Intervention with a Messenge oratory Randomized Controlled Trial |
| Name of your App/Software/In If there is a short and a long/alternate name, wr brackets. | tervention * te the short name first and add the long name in |
| | |
| KakaoTalk & Kakao Plus Friends | |
| KakaoTalk & Kakao Plus Friends Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.279 | 13" |
| Evaluated Version (if any) | 13" |
| Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.279 Your answer Language(s) * | 13" tiple languages are available, separate by comma |
| Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.279 Your answer Language(s) * What language is the intervention/app in? If mu | |
| Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.279 Your answer Language(s) * What language is the intervention/app in? If mu (e.g. "English, French") Korean URL of your Intervention Websi e.g. a direct link to the mobile app on app in app | tiple languages are available, separate by comma te or App store (itunes, Google Play), or URL of the website. |
| Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.279 Your answer Language(s) * What language is the intervention/app in? If mu (e.g. "English, French") Korean URL of your Intervention Websi | tiple languages are available, separate by comma te or App store (itunes, Google Play), or URL of the website. |

| Accessibility * Can an enduser access the intervention presently? |
|---|
| access is free and open |
| access only for special usergroups, not open |
| access is open to everyone, but requires payment/subscription/in-app purchases |
| app/intervention no longer accessible |
| Other: |
| Primary Medical Indication/Disease/Condition * e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)" office workers |
| Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial Self-Report Habit Index (SRHI) Secondary/other outcomes |
| Are there any other outcomes the intervention is expected to affect? Your answer |
| Recommended "Dose" * What do the instructions for users say on how often the app should be used? Approximately Daily Approximately Weekly Approximately Monthly Approximately Yearly "as needed" Other: |
| |

| | prox. Percentage of Users (starters) still using the app as ommended after 3 months * |
|-----|---|
| 0 | unknown / not evaluated |
| 0 | 0-10% |
| 0 | 11-20% |
| 0 | 21-30% |
| 0 | 31-40% |
| 0 | 41-50% |
| 0 | 51-60% |
| 0 | 61-70% |
| 0 | 71%-80% |
| 0 | 81-90% |
| • | 91-100% |
| 0 | Other: |
| Ove | erall, was the app/intervention effective? * |
| • | yes: all primary outcomes were significantly better in intervention group vs control |
| 0 | partly: SOME primary outcomes were significantly better in intervention group vs control |
| 0 | no statistically significant difference between control and intervention |
| 0 | potentially harmful: control was significantly better than intervention in one or more outcomes |
| 0 | inconclusive: more research is needed |
| | Other: |

| Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) |
|--|
| o not submitted yet - in early draft status |
| onot submitted yet - in late draft status, just before submission |
| submitted to a journal but not reviewed yet |
| submitted to a journal and after receiving initial reviewer comments |
| submitted to a journal and accepted, but not published yet |
| O published |
| Other: |
| Journal * If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other") |
| onot submitted yet / unclear where I will submit this |
| Journal of Medical Internet Research (JMIR) |
| JMIR mHealth and UHealth |
| JMIR Serious Games |
| JMIR Mental Health |
| JMIR Public Health |
| JMIR Formative Research |
| Other JMIR sister journal |
| Other: |
| Is this a full powered effectiveness trial or a pilot/feasibility trial? |
| O Pilot/feasibility |
| Fully powered |
| Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR) |
| no ms number (yet) / not (yet) submitted to / published in JMIR |
| Other: |

1a) TITLE: Identification as a randomized trial in the title

| yes | | | | | | |
|---|---|---|--|--|--|--|
| yes | | | | | | |
| Other: | | | | | | |
| 1a-i) Identify the mode Identify the mode Identify the mode of delivery. Prefin the title. Avoid ambiguous term Intervention includes non-web-base "electronic" only if offline products worlds). Use "online" only in the coproduct names with broader term instead of "iphone"), especially if the contract of the contract | erably use s like "onli sed Interne s are used ontext of " s for the cl | "web-bas ne", "virtu et compor Use "virt online sup ass of pr | ed" and/ al", "inter nents (e.g ual" only i oport grou oducts (s | or "mobil active". U J. email), I in the cor Jps". Con uch as "n | se "Internationse "comp ntext of "vi nplement of nobile" or | et-based" only if outer-based" or rtual reality" (3-D or substitute |
| | 1 | 2 | 3 | 4 | 5 | |
| 1.30 | | \bigcirc | 0 | 0 | | essential |
| Copy and paste relevant sections this" to indicate direct quotes fron additional information not in the n your study Intervention with a Messen | from mani n your mai ns, or brief ger Appli | uscript tit nuscript), ly explain | le (includ or elabor why the | e quotes ate on thi item is no | in quotations item by applicable. | on marks "like providing ole/relevant for |
| important Does your paper addre Copy and paste relevant sections this" to indicate direct quotes fron additional information not in the n your study Intervention with a Messen 1a-ii) Non-web-based in title Mention non-web-based compone | from manin your manins, or brief | uscript tit nuscript), ly explain cation | le (includ or elabor why the | e quotes ate on thi item is no | in quotations item by applicable applicable. | on marks "like providing ole/relevant for terventions |
| important Does your paper addre Copy and paste relevant sections this" to indicate direct quotes from additional information not in the n your study Intervention with a Messen 1a-ii) Non-web-based in title Mention non-web-based compone | from manin your manins, or brief | uscript tit nuscript), ly explain cation | le (includ or elabor why the | e quotes ate on thi item is no | in quotations item by applicable applicable. | on marks "like providing ole/relevant for terventions |
| | from manin your manns, or brief ger Appli COMPO | uscript tit nuscript), ly explain cation nents | le (includ or elabor why the or imp | e quotes ate on thi item is no | in quotation it experies it co-in the co-in th | on marks "like providing ole/relevant for terventions |
| important Does your paper addre Copy and paste relevant sections this" to indicate direct quotes from additional information not in the re your study Intervention with a Messen 1a-ii) Non-web-based in title Mention non-web-based compone telephone support"). | from manin your manins, or brief ger Appli compo | uscript tit nuscript), ly explain cation onents | or implication or imp | e quotes ate on thi item is no | in quotation it experies it co-in the co-in th | on marks "like providing ble/relevant for terventions |
| important Does your paper addre Copy and paste relevant sections this" to indicate direct quotes from additional information not in the n your study Intervention with a Messen 1a-ii) Non-web-based in title Mention non-web-based compone telephone support"). subitem not at all important | from manin your manins, or brief ger Appli components or imp | iscript tit iuscript), ily explain ication inents inents inents inents inents inents inents | or implication or imp | e quotes ate on thi item is not the contain the contai | in quotations item by the street to the stre | on marks "like providing ple/relevant for terventions e.g., "with essential on marks "like providing |

2 3 4

5

1

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

for Office Workers

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|----------|----------|
| subitem not at all important | 0 | 0 | 0 | 0 | O | essentia |

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. Background, Objective, Methods, Results, Conclusions, Trial

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|----------|---|-----------|
| subitem not at all important | 0 | 0 | 0 | O | 0 | essential |

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

fully automated

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essentia |

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all important

1 2 3 4 5

subitem not at all essential

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

intended as stand-alone intervention being more cost-effective to other interventions

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all important

1 2 3 4 5

subitem not at all essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Several treatment modalities have been designed and implemented using the habit-formation model and have suggested a promising new tool to support profound change in the way patients relate to food and physical activity. However, most of these have substantial barriers that undermine long-term strategies, such as lack of adherence to the intervention, time constraints, and lack of consistent follow-ups over the long term [7].

The use of Information and Communication Technologies, especially mobile applications, is demonstrating great potential in the delivery of treatment programs. These interventions are becoming highly valuable by promoting the continuous access of patients without the need for face-to-face meetings, home visits, or extra expenses [8]. However, most health-related applications have functions that provide information, tracking, and record activity status. These make continuous use difficult.

They can therefore be used as a tool to provide a health behavior intervention that emphasizes the importance of sustainability and involvement. It is thus necessary to develop a mobile intervention

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Thus, in this study, we aimed to assess the efficacy of the "Healthy Lifestyle Coaching Chatbot" intervention presented via a messenger application aimed at stair-climbing habit formation for office workers.

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A parallel study design was used for this exploratory trial that took place for 12 weeks from February to April 2018.

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study no changes to methods 3b-i) Bug fixes, Downtimes, Content Changes Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2]. subitem not at all essential important Does your paper address subitem 3b-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Your answer 4a) Eligibility criteria for participants Does your paper address CONSORT subitem 4a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 1) Individuals older than 24 years who could understand and respond to the survey content. 2) Individuals who understood the purpose of this research and gave written consent. 3) Users of the KakaoTalk application. 4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified. subitem not at all essential important Does your paper address subitem 4a-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

3) Users of the KakaoTalk application.

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all important O O O essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The participants were recruited from one of the advertising sharing platform. Once the participants had interests and were agreed to join the intervention, they could connect to the KakaoTalk Plus Friend ID "Healthy Lifestyle Coaching Chatbot" through a QR code and click "add friend" icon, then they were added as members automatically.

An online consent form and a prior survey link were then sent. Because only one KakaoTalk ID can be set per mobile phone number, it's possible to check the participants from manager account in real time. In process of the recruitment, about 128 participants who read the research introduction signed up through QR code.

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

subitem not at all important

1 2 3 4 5

subitem not at all essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An online consent form and a prior survey link were then sent.

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The participants were asked to perform the action based on the daily routine and the same context.

Cue was given through a push alarm sent to participants every day to alert them to perform the stair-climbing behavior. They were then asked to respond to a message sent by the chatbot. Depending on

| based trials) or otherwise. | ir-)asses | sea tilloa | gh online | question | naires (as | s common in we |
|--|--|--|--|-------------------------------------|---|---|
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |
| Does your paper addre Copy and paste relevant sections fi to indicate direct quotes from your information not in the ms, or briefly | om the n | nanuscrip ipt), or ela | t (include aborate o | n this iter | n by provi | ding additional |
| The outcomes were self-ass | essed t | hrough | the goo | gle surv | ey. | |
| 4b-ii) Report how instit Report how institutional affiliations affiliations with prestigious hospita with regards to an intervention.(No | are displ Is or univ t a require | ayed to p ersities n ed item – | otential p nay affect describe | articipan voluntee only if th | ts [on ehe r rates, us is may bia | alth media], as se, and reaction |
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all important | 0 | \circ | 0 | \circ | 0 | essential |
| Copy and paste relevant sections for the indicate direct quotes from your information not in the ms, or briefly | om the n | nanuscrip ipt), or ela | t (include aborate o | n this iter | n by provi | ding additional |
| Copy and paste relevant sections for to indicate direct quotes from your information not in the ms, or briefly Your answer 5) The interventions fo allow replication, include | rom the n manuscr explain v | nanuscrip ipt), or ela why the ito | ot (include aborate or em is not | n this iter applicable | n by provi e/relevan | ding additional it for your study |
| Copy and paste relevant sections for to indicate direct quotes from your information not in the ms, or briefly Your answer 5) The interventions for allow replication, include | rom the n manuscr explain v | nanuscrip ipt), or ela why the ito | ot (include aborate or em is not | n this iter applicable | n by provi e/relevan | ding additional it for your study |
| Copy and paste relevant sections for to indicate direct quotes from your information not in the ms, or briefly Your answer 5) The interventions for allow replication, include administered 5-i) Mention names, cresponsors, and owners Mention names, credential, affiliation authors/evaluators are owners or described in the indicator of the indica | r each ding he | al, affi | ot (include aborate or em is not o with d where liation ers, spons ftware, th | suffici n they | ent de were | ding additional of for your study stails to actually elopers, |
| Copy and paste relevant sections for to indicate direct quotes from your information not in the ms, or briefly Your answer 5) The interventions for allow replication, include administered 5-i) Mention names, cresponsors, and owners Mention names, credential, affiliation authors/evaluators are owners or described in the indicator of the indica | r each ding he | al, affi | ot (include aborate or em is not o with d where liation ers, spons ftware, th | suffici n they | ent de were | ding additional at for your study stails to actually elopers, |
| | r each ding he edenti | al, affi | ot (include aborate or em is not or with d where the control of th | sufficing they | ent de were a | ding additional at for your study stails to actually elopers, |

| | 1 | 2 | 3 | 4 | 5 | |
|---|--|--|---|--|--|--|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essentia |
| Does your paper addre | | | | e auotes i | n guotatio | on marks "like |
| to indicate direct quotes from your information not in the ms, or briefl | r manusci | ript), or el | aborate o | n this iter | n by provi | ding additiona |
| Your answer | | | | | | |
| 5-iii) Revisions and upon Revisions and updating. Clearly mapplication/intervention (and comintervention underwent major charand/or content was "frozen" during changing content which may have events see item 3b). | ention the parator, if nges durir g the trial. | applicabl ng the eva Describe | e) evalua luation pi dynamic | ted, or de rocess, or compone | scribe wh whether ents such | the developme as news feeds |
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all | \bigcirc | 0 | 0 | 0 | \bigcirc | essentia |
| important Does your paper addre Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefl Your answer | from the r r manusci | manuscrip ript), or el | ot (include aborate o | n this iter | n by provi | ding additiona |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle Your answer | from the r r manusci y explain | manuscrip ript), or el why the it | ot (include aborate o | n this iter | n by provi | ding additiona |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle | from the r r manuscr y explain | manuscript), or elawhy the it | ot (include aborate o em is not | n this iter applicab | n by provi le/relevan | ding additiona t for your stud |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle your answer 5-iv) Quality assurance Provide information on quality ass | from the r r manuscr y explain | manuscript), or elawhy the it | ot (include aborate o em is not | n this iter applicab | n by provi le/relevan | ding additiona t for your stud |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle your answer 5-iv) Quality assurance Provide information on quality ass | from the r r manuscr y explain e meth urance m | manuscript), or ela why the it ods ethods to | ot (include aborate o em is not | n this iter applicab | n by provi le/relevan | ding additiona t for your stud |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle. Your answer 5-iv) Quality assurance Provide information on quality assurance provided [1], if applicable. subitem not at all important Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle | e methourance m | nanuscripti), or eliwhy the it ods ethods to 2 oitem manuscripti), or eli | ensure a 3 5-iv? ti (include aborate o em is not | n this iter applicable ccuracy a 4 | n by provi le/relevan and quality 5 | ding additionate for your student for marks "like ding additionate for your student for you |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle. Your answer 5-iv) Quality assurance Provide information on quality assurance provided [1], if applicable. subitem not at all important Does your paper address Copy and paste relevant sections to indicate direct quotes from your | e methourance m | nanuscripti), or eliwhy the it ods ethods to 2 oitem manuscripti), or eli | ensure a 3 5-iv? ti (include aborate o em is not | n this iter applicable ccuracy a 4 | n by provi le/relevan and quality 5 | ding additionate for your student for marks "like ding additionate for your student for you |
| Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle. Your answer 5-iv) Quality assurance Provide information on quality assurance provided [1], if applicable. subitem not at all important Does your paper address Copy and paste relevant sections to indicate direct quotes from your information not in the ms, or briefle | e methor and a service of the control of the contro | nanuscriptipt), or elewhy the it | ensure a 3 5-iv? et (include aborate o em is not | ccuracy a 4 Quotes in this iter applicab | n by provi | ding additionate for your student of information essential on marks "like ding additionate for your student for your student e, and/or |

5-ii) Describe the history/development process

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all important OOOO essential

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important O O essential

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The participants were recruited from one of the advertising sharing platform. Once the participants had interests and were agreed to join the intervention, they could connect to the KakaoTalk Plus Friend ID "Healthy Lifestyle Coaching Chatbot" through a QR code and click "add friend" icon, then they were added as members automatically.

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|----------|---|----------|
| subitem not at all important | 0 | 0 | 0 | O | 0 | essentia |

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The most popular messenger application in South Korea, KakaoTalk, was used as a platform for delivering the intervention. The functions were designed based on the habit-formation model, including three elements: cue, behavior, and rewards (internal and external rewards). In addition, an automatically responding chatbot was developed using the IBM Watson Conversation tool, and it was linked to the KakaoTalk Smart Chat API through the RESTful API.

Cue was given through a push alarm sent to participants every day to alert them to perform the stair-climbing behavior. They were then asked to respond to a message sent by the chatbot. Depending on performance, a reward was sent through the KakaoTalk automatically.

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important O O O essential

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Cue was given through a push alarm sent to participants every day to alert them to perform the stair-climbing behavior.

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the intervention differed between the groups. Cues and intrinsic and extrinsic rewards were provided to the IG for the entire 12 weeks. However, intrinsic rewards were excluded for the first 4 weeks in the CG and added from the 5th to 12th weeks.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

| Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text Your answer 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial. 1 2 3 4 5 subitem not at all important Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., | The survey for measuring of and the link was sent to the application every Sunday for If the participants click the pages. | e particip or a total | ants du of 12 w | ring the eeks. | messe | nger | |
|---|--|---|--|--|--|----------------------|-------------------|
| subitem not at all important Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text Your answer 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial. 1 2 3 4 5 subitem not at all important Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). | online use and apply (questionnaires were of If outcomes were obtained through | CHERRI designe | ES ite d/dep | ms to loyed | descr | ibe ho | w the |
| Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text Your answer 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial. 1 2 3 4 5 subitem not at all important Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). | | 1 | 2 | 3 | 4 | 5 | |
| Copy and paste relevant sections from manuscript text Your answer 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial. 1 2 3 4 5 subitem not at all important Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). | | 0 | 0 | 0 | 0 | 0 | essential |
| subitem not at all important Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). | Your answer | | | | | | |
| Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). 1 2 3 4 5 subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log | ned/moding including i | easure ntensity of analysis | ed/mo of use/do , etc.). Us | nitore sage) wa | d s | |
| Copy and paste relevant sections from manuscript text Your answer 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). 1 2 3 4 5 subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log | ned/moding including i | easure ntensity of analysis n any ehe | ed/mo of use/do , etc.). Us ealth trial. | nitore sage) wa e/adoptio | d s on metrics | |
| 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). 1 2 3 4 5 subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log process outcomes that should be subitem not at all | ned/moding including i | easure ntensity of analysis n any ehe | ed/mo of use/do , etc.). Us ealth trial. | nitore sage) wa e/adoptio | d s on metrics | |
| from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). 1 2 3 4 5 subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log process outcomes that should be subitem not at all important. | ined/mo (including i gins, logfile e reported i | easure ntensity of analysis, n any ehe | ed/mo of use/do , etc.). Us alth trial. 3 | nitore sage) wa e/adoptio | d s on metrics | s are important |
| subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log process outcomes that should be subitem not at all important Does your paper addr. Copy and paste relevant sections | ined/mo (including i gins, logfile e reported i | easure ntensity of analysis, n any ehe | ed/mo of use/do , etc.). Us alth trial. 3 | nitore sage) wa e/adoptio | d s on metrics | s are important |
| subitem not at all | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log process outcomes that should be subitem not at all important Does your paper addr Copy and paste relevant sections Your answer 6a-iii) Describe wheth from participants was Describe whether, how, and when | er, how a obtain | easure ntensity of analysis, in any ehe 2 Dittem (uscript te , and veed feedback | ed/mo of use/do , etc.). Us alth trial. 3 6a-ii? xt | nitore sage) wa e/adoption 4 | d s on metrics 5 | essential eedback |
| important | 6a-ii) Describe whether use/dosage) was defined/measured/monitored (log process outcomes that should be subitem not at all important Does your paper addr Copy and paste relevant sections Your answer 6a-iii) Describe wheth from participants was Describe whether, how, and when | ined/mo (including i gins, logfile e reported i 1 O ess sub from manu er, how s obtain qualitative interviews, | easure ntensity of analysis, in any ehe 2 Ditem (uscript te , and vel feedback focus gro | ed/mo of use/do , etc.). Us alth trial. 3 6a-ii? xt when co k from pa pups). | nitore sage) wa e/adoptio 4 Qualita rticipants | d s on metrics 5 | essential eedback |

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

5

essential

subitem not at all important

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sample size was calculated based on the power analysis formula [11]. With a significance level α = 0.05, power 1- β = 0.80, and medium effect size = 0.5 set, based on a one-tailed test, and the minimum number needed for each group was 51. After assuming a 20% drop-out rate, we calculated that each group needed 61 participants for a total of 122 research participants.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Randomization were performed using random allocation software.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The block randomization were performed using R program. The number of subjects were set as 121, and the block size was set as 4

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this is kind a Online Based Trials

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

SPSS v.21 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. The general characteristics of the participants were analyzed using frequency, percentage, mean, and standard deviation. Relevant statistical analyses were first performed to verify proper randomization (independent samples t-test, χ^2 test, and Fisher's independent sample test). Repeated measures analysis of variance (ANOVA) with 12 moments was applied for measuring the changes in SRHI automaticity scores to evaluate the effect of the intervention on the two groups. The changes in physical activity levels between groups were tested with

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important

1 2 3 4 5

subitem not at all essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No imputation was performed

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

no additional analyses was perfored

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

subitem not at all important OOOO essential

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The research plan was reviewed by the Institutional Review Board of Seoul National University and received approval (IRB No. 1706/003-026), and this clinical trial was registered in the Clinical Research Information Service (https://cris.nih.go.kr, registration number: KCT0004009).

| | 1 | 2 | 3 | 4 | 5 | |
|--|---|--|--|---|--|---|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |
| Does your paper addr Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie | s from the r ur manusci | manuscrip ript), or el | ot (include aborate o | e quotes i n this iter | n by provi | ding additional |
| Your answer | | | | | | |
| X26-iii) Safety and se Safety and security procedures, i likelihood or detection of harm (e | ncl. privacy | consider | ations, ar | | | |
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |
| | | | | | | |
| Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie | from the r ur manusci | manuscrip ript), or el | ot (include aborate o | e quotes i n this iter | n by provi | ding additional |
| Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie | from the r ur manusci | manuscrip ript), or el | ot (include aborate o | e quotes i n this iter | n by provi | ding additional |
| Copy and paste relevant sections to indicate direct quotes from yo | from the r ur manusci | manuscrip ript), or el | ot (include aborate o | e quotes i n this iter | n by provi | ding additional |
| Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie Your answer RESULTS 13a) For each group, randomly assigned, re | s from the r ur manusci fly explain | manuscript), or eli why the it | of (include aborate o em is not | e quotes i n this iter applicab | n by provi le/relevan | ding additional t for your study |
| | the nur eceived ary out | manuscript), or eliwhy the it | of parded tree | e quotes in this iter applicab ticipar eatme | n by provi le/relevan nts who nt, and vention ir | ding additional t for your study O Were Were |
| Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie Your answer RESULTS 13a) For each group, randomly assigned, reanalysed for the prim | the nureceived ary out | manuscripript), or eliwhy the it why the it why the it intended come enters per eare provi | of parded treatments of parded treatments of parded treatments of parded treatments of the parde | ticipar eatme the interch center the interch center the quotes in this iter | n by provide/relevants whent, and wention in random significants whent in the second s | ding additional t for your study O Were Were n each group and on marks "like the |
| Copy and paste relevant sections to indicate direct quotes from yo information not in the ms, or brie Your answer RESULTS 13a) For each group, randomly assigned, reanalysed for the primon NPT: The number of care provide number of patients treated Does your paper address to indicate direct quotes from your paper in the primon to indicate direct quotes from your paper in the primon paste relevant sections to indicate direct quotes from your paper address to indicate direct quotes from your p | the nureceived ary out | manuscripript), or eliwhy the it intendecembers per come enters per care provi | of parded treatment of treatmen | ticipar eatme the interch center the interch center the quotes in this iter | n by provide/relevants whent, and wention in random significants whent in the second s | ding additional t for your study O Were Were n each group and on marks "like the |

x26-ii) Outline informed consent procedures

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Because performing the first action is important in habit formation, participants were asked to perform the stair-climbing and upload a proof shot. Finally, 15 participants (4 in the IG and 11 in the CG) who did not upload a picture were considered non-executers of the first action and were excluded from the study. A total of 106 participants (57 in the IG and 49 in the CG) were finally included in the 12-week intervention program (Figure 1). The intervention was performed from 1st Feb. 2018 to 30th Apr. 2018.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The intervention was performed from 1st Feb. 2018 to 30th Apr. 2018.

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

subitem not at all important OOOO essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

Does your paper address CONSORT subitem 14b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study the trial was designed for 12 weeks, and after 12 weeks it's ended.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Testing for homogeneity of general characteristics such as sex, age, physical activity status, weight control experience, weight, and hours sitting weekly between the IG and CG showed no significant differences in any of the baseline characteristics between the two groups (Table 1).

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

| | 1 | 2 | 3 | 4 | 5 | |
|---------------------------------|---|---|---|---|---|----------|
| subitem not at all important | 0 | 0 | 0 | • | 0 | essentia |

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

gender, age was asked.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

| | ' | Z | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|----------|
| subitem not at all important | 0 | 0 | 0 | • | 0 | essentia |

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After the 4th week of the intervention, the changes in the SRHI automaticity scores between the two groups were compared. The scores had increased at 13.54 points (\pm 14.99) in the IG and 6.42 points (\pm 9.42) in the CG, and there were significant differences between the two groups during that period (p = 0.035).

After the 5th week, the intrinsic reward was added to the intervention in the CG and the same intervention was provided to both groups from the 5th to 12th week. We found that the increases in the SRHI automaticity scores were 12.08 points (± 10.87) in the IG and 15.88 points (± 13.29) in the CG, with no significant difference in the changes between the two groups from the 5th to the 12th week (p = 0.211) (Table 4).

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at all important OOOO essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

95% confidence interval

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

subitem not at all important OOOO essential

Does your paper address subitem 17a-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Your answer

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No effect size was recommended

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

other analyses performed

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

subitem not at all important OOOO essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

| | 1 | 2 | 3 | 4 | 5 | |
|--|--|--|---|---|--|---|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |
| Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief | s from the r ur manusci | nanuscrip ript), or ela | ot (include aborate o | n this iter | n by provi | ding additional |
| Your answer | | | | | | |
| 19-ii) Include qualitations from standard observations from standard observations from standard observations and shortcomings of unintended/unexpected effects odd not use the application as intended. | aff/rese n participar of the applic or uses. Thi | earche nts or obs cation, es s include | rs ervations pecially if s (if availa | from sta | ff/researc | hers, if availab |
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all | | | | | | |
| important | O | O | 0 | O | O | essential |
| important | ess sul | nitem | 19-ii? | 0 | O | essential |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you | s from the r ur manusci | nanuscrip ript), or el | ot (include aborate o | n this iter | n by provi | on marks "like t ding additional |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief | s from the r ur manusci | nanuscrip ript), or el | ot (include aborate o | n this iter | n by provi | on marks "like t ding additional |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief | s from the r ur manusci | nanuscrip ript), or el | ot (include aborate o | n this iter | n by provi | on marks "like t ding additional |
| | s from the r ur manusci | nanuscrip ript), or el | ot (include aborate o | n this iter | n by provi | on marks "like t ding additional |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer | s from the r ur manusci | nanuscrip ript), or el | ot (include aborate o | n this iter | n by provi | on marks "like t ding additional |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION 22) Interpretation con | s from the r ur manuscr fly explain | nanuscript), or elewhy the it | ot (include aborate o em is not | n this iter applicab | n by provi le/relevan | on marks "like t ding additional t for your study |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION 22) Interpretation con | s from the r ur manuscr fly explain | nanuscript), or elewhy the it | ot (include aborate o em is not | n this iter applicab | n by provi le/relevan | on marks "like t ding additional t for your study |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION | s from the r ur manuscr fly explain v | manuscriptipt), or elewhy the it with rother a | ot (include aborate o em is not results relevar | n this iter applicab s, balar nt evid | n by provi le/relevan ncing t lence | on marks "like t ding additional t for your study Denefits |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION 22) Interpretation con and harms, and consi NPT: In addition, take into account and unequal expertise of care page 22-i) Restate study questions. | s from the r ur manusci fly explain v dering ount the ch providers of | manuscriptipt), or eliwhy the it with rother in the or center is and si | results releval the comps in each | n this iter applicab , balar nt evid arator, la group | ncing blence | on marks "like t ding additional t for your study Denefits Dartial blinding |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION 22) Interpretation con and harms, and consi NPT: In addition, take into account and unequal expertise of care particularly and unequal expertise of care process outcomes (use Restate study questions and sur | a from the rur manuscrifly explain values the characteristic dering count the characteristic derivative country countr | manuscriptipt), or elewhy the it with rother to contered and sing with | results releval he comp s in each | n this iter applicab , balar nt evid arator, la group arize t | ncing blence | on marks "like t ding additional t for your study Denefits Dartial blinding |
| important Does your paper addr Copy and paste relevant sections to indicate direct quotes from you information not in the ms, or brief Your answer DISCUSSION 22) Interpretation con and harms, and consi | a from the rur manuscrifly explain values the characteristic dering count the characteristic derivative country countr | manuscriptipt), or eliwhy the it with rother incorder of the content or center in grand stands and stands and stands and with the content of the content or center in grands and stands and with the content of the con | results releval he comp s in each | n this iter applicab , balar nt evid earator, la group arize t nary ou | ncing blence ck of or place | on marks "like t ding additional t for your study Denefits Dartial blinding |

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study shows that the "Healthy Lifestyle Coaching Chatbot" program results in effective habit formation for stair-climbing behavior. Habit is an automatic behavior gained via repetition. In this study, most participants tended to increase the number of repetitions of the behavior and thus increase the habit strength as the intervention proceeded. This suggests that, according to the habit-formation model hypothesis, given a consistent context, the repeated occurrence of cuebehavior-reward chains leads to increases in the strength of the habit behavior [15].

In this study, we measured effectiveness based on the reward-type differences between the IG and the CG. A fundamental distinction can be drawn between extrinsic rewards (e.g., financial incentives) and intrinsic rewards (e.g., pleasure, satisfaction) [16]. This concurs with other studies that suggest that extrinsic rewards elicit intrinsic motivation regarding the behavior initially, but later decrease the intrinsic motivation as the behavior continues [17]. Analysis of the changes in habit strength (SRHI automaticity scores) at week 4 of the intervention showed that the changes were greater for the IG than for the CG at a statistically significant level. We then provided both intrinsic and extrinsic rewards to both groups similarly. The changes in the habit strength of the two groups showed significant increase without a significant between-group difference. This indicates that intrinsic rewards maintain the sustainability of behavior and that they play an important role in the formation of habit. The results of our study suggest the need for many interventions using intrinsic reward factors when designing an intervention program. Furthermore, positive feedback such as using a "compliment" as an intrinsic reward is a simple but powerful tool in which the positive value of the reward can act as a motivational factor [16].

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

| non-use of the intervention/usabili unexpected events. | ty issues, | Diases th | irougn ini | | | 3334 |
|--|--|--|---|--|--|--|
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all important | 0 | 0 | 0 | O | 0 | essential |
| to indicate direct quotes from your information not in the ms, or briefly Limitations There are limitations in desi provided by the current mes communication functions, so commitments and receiving Further research should be to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify how the rewards important to maintaining has 21) Generalisability (expenses to identify has a contract to identify has a contract to identify how the rewards important to maintaining has a contract to identify high has a contract to identify high has a contract to identify high has a contract to identify ha | gning th senger a uch as i positive done to affect th bits. | e prograpplication of the prograpplication of the program of the p | em is not am beca ion doe ng collea rt mess ent diffo s and w | ause the s not in agues o ages fr erent kin hich on | e function clude distributed their om other ands of relations the | onality irect ers. ewards |
| findings NPT: External validity of the trial patients, and care providers or continuous continuous care providers or care p | findings enters in O other as: In part g, and ger | accordir volved in POPU icular, dis | ng to the the trial lations | interven S eralizabili | ity to a ge | nparators, eneral Internet |
| findings NPT: External validity of the trial patients, and care providers or contained to the second secon | findings enters in O other as: In part g, and ger | accordir volved in POPU icular, dis | ng to the the trial lations | interven S eralizabili | ity to a ge | nparators, eneral Internet |
| findings NPT: External validity of the trial patients, and care providers or contained to the second secon | findings enters in o other as: In part g, and gen | accordir volved in popu icular, dis neral pati | ng to the the trial lations cuss gen ent popul | interven S eralizabili ation, inc | tion, com | nparators, eneral Internet |
| NPT: External validity of the trial patients, and care providers or continuous continuous care providers or care provi | findings enters in other as: In part g, and gents 1 ess subtrom the narranser y explain where elements in the selement in the | according volved in volved in volved in volved in volumental patients could vement, thents could very volved in volved vement, thents could very volved in volved very volved in volved very volved in volved very very volved very very volved very very very very very very very very | lations cuss genent popul 3 21-i? ot (include aborate o em is not etting be differeraining se | e quotes in this iterapplicab | tion, comity to a ge luding appoint of that appoint of the company | eneral Internet plicability of the essential on marks "like thiding additional at for your study would be blication setting printerventions) |
| NPT: External validity of the trial patients, and care providers or contents. 21-i) Generalizability to Generalizability to Generalizability to other population population, outside of a RCT setting study results for other organization. Subitem not at all important. Does your paper address to indicate direct quotes from your information not in the ms, or briefly Your answer. 21-ii) Discuss if there we different in a routine and Discuss if there were elements in the (e.g., prompts/reminders, more hull and what impact the omission of the contents or contents. | findings enters in other as: In part g, and gents 1 ess subtrom the narranser y explain where elements in the selement in the | according volved in volved in volved in volved in volumental patients could vement, thents could very volved in volved vement, thents could very volved in volved very volved in volved very volved in volved very very volved very very volved very very very very very very very very | lations cuss genent popul 3 21-i? ot (include aborate o em is not etting be differeraining se | e quotes in this iterapplicab | tion, comity to a ge luding appoint of that appoint of the company | eneral Internet plicability of the essential on marks "like thiding additional at for your study would be blication setting printerventions) |

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

CRIS Registration Number: KCT0004009 / Unique Protocol ID: 1706/003-026

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=14100<ype=&rtype=

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

| | I | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---------|---|-----------|
| subitem not at all important | 0 | 0 | 0 | \circ | 0 | essential |

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

About the CONSORT EHEALTH checklist

| As a result of using this checklist, did you make changes in your manuscript? * |
|--|
| O yes, major changes |
| yes, minor changes |
| O no |
| What were the most important changes you made as a result of using this checklist? |
| Your answer |
| |
| How much time did you spend on going through the checklist INCLUDING making changes in your manuscript * |
| a week |
| As a result of using this checklist, do you think your manuscript has improved? * |
| yes |
| O no |
| Other: |
| W. II. III. II. II. OONOODT EUEALTU |
| Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document |
| O yes |
| O no |
| Other: |
| Any other comments or questions on CONSORT EHEALTH |
| Your answer |
| Tour answer |

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service

Google Forms